CAR-T– tag –
-
Strategic Capital Influx in Gene Therapy: Pfizer Invests in CRISPR Biotech, AstraZeneca Strengthens China Cell Therapy Capabilities
BioPharma Dive USA Overview The gene therapy sector is experiencing a surge in strategic funding and M&A activities from major pharmaceutical companies. Pfizer has invested in CRISPR biotech Caribou Biosciences, while AstraZeneca pla... -
CAR-NK Cell Therapy for Solid Tumors: Promising Safety and Off-the-Shelf Potential Outpace CAR-T
Cell Reports Medicine (via PubMed) USA Overview A new review highlights chimeric antigen receptor (CAR)-modified natural killer (NK) cells as a promising immunotherapy strategy for solid tumor treatment. Compared to CAR-T cell therapy, C... -
China Grants World’s First Solid Tumor CAR-T Approval for Satri-cel in Advanced Gastric Adenocarcinoma
Fierce Biotech USA Overview China's National Medical Products Administration (NMPA) has approved CARsgen Therapeutics' solid tumor CAR-T cell therapy, satri-cel, for HER2-negative, Claudin18.2-positive advanced gastric and gastroesophage... -
Cell Therapy Scale-Up and CDMO Staff Reductions Trigger Critical Process Know-How Loss in Tech Transfer
Drug Discovery and Development USA Overview The scaling of cell therapies, coupled with staffing changes at Contract Development and Manufacturing Organizations (CDMOs), is leading to a significant loss of critical process know-how durin... -
CAR-T Cell Therapy for Autoimmune Diseases Achieves 40-60% Cost Reduction and Sub-7-Day Manufacturing Through Gene Editing and Process Optimization
Market Intelo USA Overview Advances in gene-editing technologies are significantly reducing alloreactivity risk in allogeneic CAR-T products and cutting production costs by an estimated 40-60%. Next-generation allogeneic platforms aim to... -
iPSC-Derived Immune Cells Pave Way for Scalable Allogeneic T-Cell Therapy Platforms in Cancer Immunotherapy
MDPI Global Overview Allogeneic T-cell therapies are rapidly advancing as a promising strategy in cancer immunotherapy to overcome the logistical and manufacturing challenges inherent in autologous approaches. Crucially, induced pluripot... -
European Biotechs Lead Next-Gen Cell & Gene Therapy Manufacturing Innovation: From Scalable Stem Cells to Clinical CAR Treg Trials
PharmTech ヨーロッパ Overview European biotech companies are pioneering next-generation manufacturing technologies crucial for the commercial viability and accessibility of cell and gene therapies (CGTs), prioritizing scalable allogeneic... -
Europe’s Regulatory Frontier for Advanced Biologics: Real-World Evidence and Patient Voices Shape Cell and Gene Therapies
ResearchGate (論文) Global Overview A new ResearchGate paper explores Europe's progressive regulatory landscape for advanced cell and gene therapies, a class of complex, engineered biologics. It underscores the critical role of integrati... -
Long-Read DNA Sequencers Market to Accelerate by 2035 Amid Biopharma Quality Control Demand: Essential for CAR-T Genomic Evaluation
IndexBox News and Statistics Global Overview The long-read DNA sequencer market is projected for accelerated growth by 2035, driven by biopharmaceutical quality control demands, particularly the need for high-resolution genomic evaluatio... -
Advances in Multiple Myeloma Treatment: CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates Evolving in Approved & Clinical Stages
Myeloma Crowd USA Overview An article summarizing the latest advancements in multiple myeloma treatment highlights the diversification of approved and investigational approaches, including CAR-T cell therapies, bispecific T-cell engagers...
